NCT07158489
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07158489
Title Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC (ORIGIN2)
Acronym ORIGIN2
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Swiss Cancer Institute
Indications
Therapies
Age Groups: senior | adult
Covered Countries CHE

Facility Status City State Zip Country Details
Kantonsspital Baden Baden 5404 Switzerland Details
Universitätsspital Basel Basel 4031 Switzerland Details
IOSI Ospedale Regionale di Bellinzona e Valli Bellinzona 6500 Switzerland Details
Kantonsspital Graubuenden Chur CH-7000 Switzerland Details
Hôpital Fribourgeois - Hôpital Cantonal Fribourg Switzerland Details
Hôpitaux Universitaires de Genève Geneva 1211 Switzerland Details
Kantonsspital Winterthur Winterthur 8401 Switzerland Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field